We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Microfluidic Chip Method to Improve Sepsis Diagnosis, Progression Evaluation and Prognosis Monitoring

By HospiMedica International staff writers
Posted on 27 Sep 2024

Sepsis, a severe and life-threatening condition, results from an uncontrolled immune response that can lead to multi-organ failure. More...

Given its high mortality rate and the limitations of current diagnostic and monitoring methods, there is an urgent need to develop better tools for evaluating and managing sepsis. A research team has now introduced a novel prognostic evaluation method for sepsis patients using a microfluidic concentration gradient chip.

In this study, conducted by researchers at the Hefei Institutes of Physical Science of the Chinese Academy of Sciences (Hefei, China), a microfluidic chip was employed to analyze the chemotactic migration behaviors of neutrophils and T lymphocytes in sepsis patients. The researchers observed significant differences in neutrophil migration parameters between sepsis patients and healthy controls, including gradient sensing time, migration distance, peak velocity, and the chemotactic index. From these findings, they developed a comprehensive evaluation index for neutrophil migration function, which showed a strong correlation with established markers of sepsis severity and commonly used biomarkers. These results were published in Talanta.

The research team also investigated T-cell migration in sepsis patients using the microfluidic platform. They found that sepsis patients had impaired T-cell migration and elevated NADH/NAD+ levels. Further experiments suggested that these elevated levels were caused by alterations in the plasma microenvironment, likely due to mitochondrial dysfunction. By administering the mitochondrial-targeted drug MitoQ, the researchers were able to reverse these abnormalities and restore T cell migration function, offering a potential therapeutic strategy for sepsis. Related findings were published in SHOCK.

These studies present a promising new approach for diagnosing sepsis, evaluating disease progression, and monitoring prognosis. The development of a comprehensive index and the potential use of mitochondrial-targeted therapies offer new theoretical insights and could significantly enhance sepsis management and improve patient outcomes.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
High Pressure Balloon Catheter
UroMax Ultra
New
High-Precision QA Tool
DEXA Phantom
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The milli-spinner can shrink blood clots without rupturing them (Photo courtesy of Andrew Brodhead/Stanford)

New Technology More Than Doubles Success Rate for Blood Clot Removal

In cases of ischemic stroke, where a blood clot obstructs oxygen supply to the brain, time is critical. The faster the clot is removed and blood flow restored, the more brain tissue can be saved, improving... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.